MDxHealth SA reported a net loss of $20.4 million and revenue of $51.1 million for the six months ended June 30, 2026. The company discontinued its Resolve UTI testing business and closed its Plano, Texas laboratory in May 2026, classifying it as a discontinued operation with a net loss of $1.2 million. On August 13, 2026, MDxHealth completed a registered direct placement of 44,052,862 ordinary shares at $0.454 per share, raising $20 million in gross proceeds to address liquidity concerns. The company remains in non-compliance with Nasdaq's minimum bid price requirement, facing a compliance deadline of December 28, 2026. MDxHealth operates in the precision diagnostics industry, developing and commercializing genomic testing solutions for prostate cancer.

MDxHealth SA issued and sold 44,052,862 ordinary shares in a registered direct offering at $0.454 per share to institutional investors on August 13, 2026. The transaction generated approximately $20.0 million in net proceeds before expenses, which the company intends to use for working capital, product development, and commercialization expansion. Post-offering, total outstanding shares increased to 95,417,382. MDxHealth SA operates in the healthcare diagnostics industry, developing non-invasive tests for colorectal cancer screening.

MDxHealth SA reported second quarter 2026 revenue of $27.2 million, a 16% increase year-over-year and a $3.3 million sequential rise from Q1. The company maintained its full-year 2026 revenue guidance of $110-115 million. Operating loss widened to $5.1 million due to expenses from the ExoDx acquisition, resulting in a net loss of $9.5 million and negative adjusted EBITDA of $(2.3) million. Concurrently, MDxHealth executed a registered direct placement of 44,052,862 ordinary shares at $0.454 per share, raising $20 million in gross proceeds to strengthen its balance sheet. The firm also finalized the wind-down of its discontinued Resolve mdx business through an Assignment for the Benefit of Creditors. MDxHealth SA operates in the precision diagnostics industry, providing molecular tests for prostate cancer and urologic diseases.

Mdxhealth SA received a notification from Nasdaq stating that its Market Value of Listed Securities was below the $35 million minimum requirement for the period from June 1, 2026, to July 17, 2026. The company has a 180-day compliance period ending January 19, 2027, to regain compliance. Mdxhealth is a urology-focused precision diagnostics company providing molecular information for prostate cancer diagnosis and treatment.

MDxHealth SA received a notice from Nasdaq indicating non-compliance with the $1.00 minimum bid price requirement after its ordinary shares closed below $1.00 for 30 consecutive trading days. The company has a 180-day compliance period ending December 28, 2026, to regain compliance by meeting the $1.00 threshold for 10 consecutive trading days. MDxHealth SA is a molecular diagnostics company providing clinical testing services.